Home › Castration-Resistant Prostatic Cancer › Pennsylvania › Philadelphia
Castration-Resistant Prostatic Cancer clinical trials in Philadelphia, PA
4 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
RecruitingPhase 3
- Penn Medicine Abramson Cancer Center, Philadelphia
- MidLantic Urology, Bala-Cynwyd · 5 mi away
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 3
- MidLantic Urology, Bala-Cynwyd · 5 mi away
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RecruitingPhase 1
- Thomas Jefferson University Honickman Center, Philadelphia
Castration-Resistant Prostatic Cancer trials in other cities
- Los Angeles, CA8 studies
- New York City, NY7 studies
- Seattle, WA6 studies
- Houston, TX6 studies
- Boston, MA5 studies
- Queens, NY4 studies
- Pittsburgh, PA4 studies
- Mountain View, CA3 studies
- Cincinnati, OH3 studies
- San Francisco, CA3 studies
- Baltimore, MD3 studies
- Nashville, TN3 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.